**Review Article** **CODEN: IJRPJK** **ISSN: 2319 – 9563**

**International Journal of Research in Pharmaceutical and Nano Sciences**

**Journal homepage: www.ijrpns.com**

https://doi.org/10.36673/IJRPNS.2021.v10.i05.A39

# REMDESIVIR – COMPLITE PHARMACOLOGY

**Sambhav Pathak*[1], Parth Verma[1], Kriti Dabral[1], Shiba S. Morris[2]**

[1*]Department of Pharmacy, Kukreja Institute of Pharmaceutical Sciences, Jhajra, Dehradun, Uttarakhand, India.
[2]Department of Pharmacy, Gyaniindersingh Institute of Professional Studies, Dehradun, Uttarakhand, India.

**ABSTRACT**

Remdesivir as a drug attracted a very severe consideration of complete Globe in treatment of the pandemic sickness COVID-19. Extra recently posted in-vitro inhibition hobby and *in-vivo* case research were showing promising clinical results and final results of powerful inhibition of SARS-CoV-2 virus through using remdesivir. However at the equal time, use of the remdesivir showed enormous detrimental detrimental events in patients which wishes a unique attention all through remedy route of COVID-19. As a result, the usage of remdesivir in treatment of COVID-19 is having present day international hobby even though a few greater scientific evidences are nevertheless important in order to recognize the actual performance and mechanism of remdesivir towards COVID-19. In this review, the literature look at highlight the modern-day ongoing studies related to use of remdesivir which includes (1) pharmacology of remdesivir (2) mechanism of action of remdesivir (3) *in-vitro* inhibition of remdesivir in opposition to SARS-CoV-2 virus, (4) *in-vivo* analysis and scientific use of remdesivir in opposition to COVID-19. Eventually viable unfavorable events are also mentioned thinking about the pharmacovigilance situation.

**KEYWORDS**

Remdesivir, COVID-19, Remdesivir side effects, Remdesivir pharmacology and SARS-CoV-2 virus.

**Author for Correspondence:**

Sambhav Pathak,
Department of Pharmacy,
Kukreja Institute of Pharmaceutical Sciences,
Jhajra, Dehradun, Uttarakhand, India.

**Email:** shibamorris14@gmail.com

## INTRODUCTION

COVID-19 is the acronym that is used for the novel coronavirus ailment-2019, which is triggered due to newly rising delta-coronavirus named as SARS-CoV-2[1-3]. The primary case of COVID-19 changed into seemed in December 2019 in Wuhan city of Hubei province china and through February 2020, it's miles declared as global pandemic with the public health emergency due to its greater contagious nature than that of SARS-CoV and

MERS-CoV[3]. Studies related to COVID-19 remains taking place concerning to actual starting place, transmission, clinical capabilities, mechanism of infectivity and use of drug to cure COVID-19. until date numerous considerable breakthroughs have been suggested in literature concerning to (i) COVID-19 scientific manifestation, (ii) genetic series with phylogenic courting of SARS-CoV-2 virus and (iii) feasible *in-vitro*- prohibition of SARS-CoV-2 virus through numerous to be had chemical drugs[4]. However, until date no drug is authorised by FDA to apply in opposition to COVID-19 remedy, whilst maximum of the medication are used at the foundation of drug repurposing idea to deal with COVID-19[5].

For this reason the use of the remidesivir drug inside the remedy of COVID-19 own extraordinary global interest at present, although collective consensus has not been attained yet which may additionally need more scientific facts, clinical trails outcome and evidences so as to prove the efficacy of the remdesivir against COVID-19[6]. The present evaluate article is aimed to spotlight (i) the antiviral use to remdesivir against various viral illnesses (ii) viable mechanism of remdesivir in opposition to viral infection, (iii) *in-vitro* inhibition of SARS-CoV-2 virus through remdesivir (iv) current scenario of use of remdesivir in opposition to COVID-19 based totally on to be had case research/ clinical trials and (v) pharmacovigilance concerns approximately use of remdesivir pharmacokinetics and use of remdesivir as an anti-viral agent.

further research literature stated anti-viral use of remdesivir towards numerous coronaviruses such MERS-CoV, SARS-CoV, δ-corronaviruses circle of relatives[7-11] hepatitis C virus, nipah, marburg, enterovirus, Filo-, Pneumo- and Paramyxo-viruses[12-16].

In recent scenario, remdesivir is used to treat against COVID-19 which may additionally have possesses aspect outcomes. Except this, remdesivir may additionally be taken into consideration as a more secure drug than that of hydroxychloroquine because, halflife of remdesivir is a good deal less in comparison to that of hydroxychloroquine[17]. Nearly 21% hydroxychloroquine in body remained unchanged even as that of remdesivir is simply most effective 10%[17-20]. Remdesivir confirmed faster clearance because of its terrible hepatic balance and consequently recommended thru IV administration[12-21]. Remedesivir confirmed much less harmful metabolites (triphosphate) than that of hydroxychloroquine (desethyl hydroxychloroquine). Drug interaction and diverse side effects are very widely known approximately hydroxychloroquine which entails the headache, cardiovascular activities, QT prolongation, conduction issues, ventricular tachycardia and retinopathy etc[22,23].

The advers effect of the remdesivir are not well known available besides to that of encephalopathy which is proven by acyclovir a nucleoside analogue comparable to that of remdesivir[20]. More these days, the FDA Emergency Use Authorization suggests a loading dose of two hundred mg (5mg/kg) once in an afternoon in sufferers ≥ 40kg and 100mg from day 2 (2.5mg/kg).

## PHARMACOLOGICAL PROFILE[17-23,20]

Remdesivir - half of-life time 20 hours.

Route of elimination - 74% removed in urine, 10% is unchanged, 18% removed in feces.

Absorption and clearance - terrible hepatitis balance, subsequently quicker clearance alter administrated via IV.

Metabolites - Triphosphate metabolite.

Drug interaction - Drug interaction not known or not available.

Toxicity - now not well pronounced in literature, at the same time as Encephalopathy is pronounced by means of comparable analogues drug.

## REMDESIVIR - POSSIBLE MECHANISM OF ACTION

Remdesivir is closely resemble to adenosine[20,24,25,17,26]. The energetic form of drug metabolite is nucleside triphosphate remdesivir and remdesivir (GS-441524) that's to be had inside the cytoplasm[24] after metabolism and unable to diffuse back to extracellular medium. This active form remdesivir (available in cyctoplasm) is utilized by

the cell viral RNA dependent RNA polymerase instead of the adenosine during the process of viral genetic material replication which is incorporated into the growing viral genetic strand instead of adenosine[26]. This incorporation in the viral genetic material not only stops the replication process bus also unable to repair viral genetic materials[25,17]. It is well identified that, lung is the most affected organ in coronavirus disease[1-2]. In lungs the type II alveolar cells incorporates large range of ACE-2 (angiotensin-changing enzyme-2) which acts as recognized receptors in which the spike (S) protein of the SARS-CoV-2 binds[27]. In addition, density of the ACE-2 receptor can also range from organ to organ and therefore it may be possible that, SARS-CoV-2 virus may also show its contamination ability in the gastrointestinal tract, gastric glandular cells, duodenal, rectal epithelium cells, Leydig cells, renal tubular cells, seminiferous ducts additionally wherein ACE-2 expression gift[20,24,25]. It is also reported that, gastrointestinal tract, kidney and testis may causes damage after SARS-CoV-2 infection due to presence of ACE-2 expression.

However its reported that, remdesivir distributed and absorbed easily in testes and epididymis immediately after four hours of administartion[17-20]. Two facts cautioned that, remdesivir may be powerful towards the SARS-CoV-2 virus as it can inhibit the virus replication inside the cellular organ in which SARS-CoV-2 receptor ACE-2 expression is available. Thus the gift supporting literature evidences advocate theoretical effectiveness of the remdesivir in the COVID-19 treatment[28-31]. *In-vitro* inhibition of SARS-CoV-2: Currently various reports are available which stated that for in-vitro inhibition of coronavirus (SARS-CoV-virus, MERS-CoV-virus, HCoV-OC43-virus, HCoV-229E-virus and SARS-CoV-2-virus) by way of remdesivir. *In-vitro* inhibition of the remdesivir towards SARS-CoV-2 virus could be very nicely documented inside the FDA file.

European Medicine Agency documented the *in-vitro* efficacy of the remdesivir towards SARS-CoV-2 virus[32]. Choy *et al*. Pronounced EC50 price of 23.15μM towards SARS-CoV-2 virus[33]. Wang *et al*, referred to EC50 value of 0.77μM with the selectivity index (SI) of 129 towards SARS-CoV-2 virus[24]. But, Sheahan *et al*. Mentioned the IC50 price of 0.069μM and 0.074μM for SARS and MERS coronaviruses[34]. In addition, Sheahan *et al*. Referred to EC50 fee of 8μM for the MERS coronaviruses[7]. Different researchers ie Brown *et al*[42] and Agostini *et al*. B also demonstrated that, remdesivir shows inhibitory effect in opposition to diverse coronaviruses[9,35]. Pruijssers *et al*. found EC50 cost of 0.01μM even as[36], Wang *et al*. Discovered EC50 value of 0.46 μg/mL for the inhibitory effect of remdesivir against the SARS-CoV-2 virus[6].

Accordingly the *in-vitro* analysis examine helps possible therapeutic use of remdesivir in opposition to the SARS-CoV-2 virus contamination (COVID-19).

Considering the *in-vitro* evaluation it may be feasible to use remdesivir in opposition to COVID-19. Very few case research are to be had which displayed the function of remdesivir in COVID-19 treatment. Wang *et al*. Studied use of remdesivir in adults having severe COVID-19 signs and symptoms in which clinical development is not observed through use of remdesivir[37].

In this 102/158(66%) patient sufferers confirmed detrimental results through use of remdesivir than that of 50/79(64%) patients in control group. Hence the remdesivir did not show higher use andimprovement may additionally be due to elderly (median age sixty five years) COVID-19 patients. Forty Grein *et al*, stated compassionate use of remdesivir towards COVID-19 in which[34] (68%) patients showed clinical benefits, eight (15%) sufferers showed worsen situation, even as[7] (13%) patients have been died[38]. Beigel *et al*, reported preliminary commentary for use of remdesivir towards COVID-19. In this observe, patient given remdesivir had been recovered in 9-12 days than that of control sufferers which have been recovered in 13-19 days[39]. Mortality price was 7.1% in studied remdesivir organization than that of 11.9% in control group. Negative activities were mentioned

in 21.1% sufferers administered with remdesivir, than that to 27.8% sufferers in control. Goldman et al. proposed use of remdesivir for five or 10 days in COVID-19 sufferers in which clinical improvement has been discovered by means of use of remdesivir in 64% sufferers (5 day institution) and fifty four% sufferers (10 day organization) alongside with a few everyday destructive events[40]. Apart from this Hillaker *et al* and Kujawski *et al*. Also used remdesivir against COVID-19, but there sample size is simply too small to decide the precise clinical outcome of use of remdesivir in treatment of COVID-19[41,42]. As a consequence from the to be had case research, one can expected that, remdesivir can paintings efficiently in early phase of disorder in treatment of COVID-19 but, its use can be restricted by means of a few common aspect results which are under investigational have a look at[43]. The wide variety of studies and confirmed outcome can be expected for use remdesivir against COVID-19 in coming days Prophylactic use and aspect impact of remdesivir: very few reviews are available for the proposed prophylactic use of remdesivir in opposition to COVID-19.

European medicine agency documented the prophylactic use of remdesivir which reduces the viral load significantly[32]. Sheahan *et al* and de Wit *et al*, proposed that, prophylactic use of the remdesivir may additionally save you the physiological disorder took place due to SARS-CoV-2 infection[8,10]. Agostini *et al*, additionally mentioned the prophylactic efficacy of remdesivir in opposition to diverse coronavirus sicknesses[9]. As a result from the to be had literature it might also be possible that, remdesivir confirmed its powerful prophylactic and therapeutic use against COVID-19. But, more evidences are still looking forward to in order to recognize the efficient prophylactic use of remdesivir in opposition to COVID-19. Further, it is noteworthy to mention unfavourable affect of remdesivir in gift scientific emergency state of affairs. Goldman *et al*[40]. Referred to negative occasions of use of remdesivir which entails the nausea (in 9% sufferers), worsening or breathing failure (in 8% patients), increased alanine aminotransferase stage (in 7% patients) and constipation (in 7% patients). Beigel *et al*, mentioned anemia (in 7.9% patients than 9.0% of manage organization)[44] pyrexia (in 5.0% sufferers than three% of manage group); hyperglycemia (in 4.1% patient than 3% of control institution) and extended aminotransferase. Grein *et al*, suggested detrimental activities in 60% patents during treatment which entails the expanded liver enzymes, diarrhoea, renal impairment, and hypotension, while 23% patients showed excessive destructive results such as multiple-organ-dys functioning, septic surprise, kidney damage[38]. Wang *et al*, additionally suggested common facet consequences in use of remdesivir which entails constipation, hypo-albuminaemia, anaemia, thrombocytopenia, and multiplied bilirubin[37]. Hence the use of remdesivir might also have excessive facet effects subsequently use of the remdesivir need to be administrated best under medical supervision.




## CONCLUSION

In conclusion, remdesivir pro-drug (GS-5734) can be correctly used in the remedy of viral infections. Use of this seasoned-drug basically gives lively form remdesivir (GS-441524) metabolites into the cytoplasm. This metabolite interfere the RNA replication process of the SARS-CoV-2 virus through incorporation within the viral genetic cloth synthesis process and stops the duplicate of new virus debris. Furthermore, *in-vitro* evaluation look at showed great discount of the viral load through use of remdesivir which supports the healing use of remdesivir against the SARS-CoV-2 virus infection. *In-vivo* evaluation also demonstrated the sizeable function of the remdesivir in treatment COVID-19 with some damaging occasions. However prophylactic use of the remdesivir desires some greater attention in healing use. Consequently the usage of remdesivir against COVID-19 is having fantastic international interest which desires in addition extra assisting evidences to apply remdesivir effectively in commonplace training to therapy COVID-19.

## ACKNOWLEDGEMENT

The authors wish to express their sincere gratitude to Department of Pharmacy, Gyaniindersingh Institute of Professional Studies Dehradun, Uttarakhand, India for providing necessary facilities to carry out this review work.

## CONFLICT OF INTEREST

We declare that we have no conflict of interest.

## REFERENCES

1. Badgujar K C, Badgujar A B, Patil V P, Dhangar D V. Hydroxychloroquine for COVID-19: A review and a debate based on available clinical trials/case studies, *JDDT,* 10(3), 2021, 304-311.
2. Badgujar K C, Patil D V, Dhangar D V, Patil V P, Badgujar A B. COVID-19: Epidemiology, clinical characteristics and potential possible treatment based on available studies, *Coronaviruses Journal, Bentham Science Publication*.
3. Badgujar K C, Badgujar V C, Badgujar S B. Coronavirus vaccine development (2003 to present): An overview, recent advances, current scenario, opportunities and challenges, *Dia and Meta Syn Cli Res and Rev,* 14(5), 2020, 1361-1376.
4. Singh A, Shaikh A, Singh R, Singh A K. COVID-19: From bench to bed side [published online ahead of print, 2020 Apr 9], *Dia Metab Syndr,* 14(4), 2020, 277-281.
5. FDA. U.S. Food and Drug Administration, *FDA,* 2020, 1-7.
6. Singh A K, Singh A. Remdesivir in COVID - 19: A critical review of pharmacology, pre-clinical and clinical studies, *Dia Meta Syndr,* 14(4), 2020, 641-648.

7. Sheahan T P, Sims A C, Leist S R, *et al*. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir and interferon beta against MERS-CoV, *Nat Commun,* 11(1), 2020, 222.
8. De Wit E, Feldmann F, Cronin J, *et al*. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, *Proc Natl Acad Sci USA*, 117(12), 2020, 6771-6776.
9. Agostini M L, Andres E L, Sims A C *et al*. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proof reading exoribonuclease, *MBio,* 9(2), 2018, e00221-18.
10. Sheahan T P, Sims A C, Graham R L, *et al*. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, *Sci Transl Med,* 9(396), 2017, eaal3653.
11. Brown A J, Won J J, Graham R L, Dinnon K H, Sims A C, Feng J Y, Cihlar T, Denison M R, Baric R S, Sheahan T P. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase, *Antiviral Res,* 169, 2019, 104541.
12. Gudipati, Pavan, Biswas, Shyamasri, Goyal, Pankaj. Anti hepatitis C viral drugs remdesivir and uprifosbuvir derivatives are better inhibitors of SARS Cov2 RNA - dependent RNA polymerase determined by docking studies, *Chem Rxiv,* Preprint, 2020.
13. Lo M K, Feldmann F, Gary J M, *et al*. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge, *Sci Transl Med,* 11(494), 2019, eaau9242.
14. Porter D P *et al*. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with marburg virus, *The Journal of Infectious Diseases,* 222(11), 2020, 1894-1901.
15. Ye W, Yao M, Dong Y, *et al*. Remdesivir (GS-5734) impedes enterovirus replication through viral RNA synthesis inhibition, *Front Microbial,* 11, 2020, 1105.
16. Lo MK, Jordan R, Arvey A, *et al*. GS-5734 and its parentnucleoside analog inhibit Filo-, Pneumo- and Paramyxoviruses, *Sic Rep,* 7, 2017, 1-7.
17. Tchesnokov E P, Feng J Y, Porter D P, Gotte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir, *Viruses,* 11(4), 2019, 326.
18. Warren T K, *et al*. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, *Nature,* 531(7594), 2016, 381-385.
19. https://www.drugbank.ca/drugs/DB01611#reference-L8072.
20. Furst D E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases, *Lupus,* 5(1), 1996, S11-S15.
21. Fact sheet for healthcare providers emergency use authorization (eua) of veklury® (remdesivir) for hospitalized pediatric patients weighing 3.5kg to less than 40kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5kg, *Gilead Sciences, Inc,* 2020, 1-36.
22. Remdesivir is a nucleoside analog used to treat RNA virus infections including COVID-19, *Remdesivir*.
23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf.
24. Summary on compassionate use, *European Medicines Agency,* 2020, 1-45.
25. Vander T, Medvedovsky M, Herishanu Y. Encephalopathy induced by oral acyclovir in a patient with normal renal function, *J Infect,* 46(4), 2003, 286.
26. Eastman R T, Roth J S, Brimacombe K R, Simeonov A, Shen M, Patnaik S, Hall M D. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19, *ACS Cent. Sci,* 6(5), 2020, 672-683.

27. Al-Tannak N F, Novotny L, Alhunayan A. Remdesivir -bringing hope for COVID-19 Treatment, *Sci. Pharm,* 88(2), 2020, 29.
28. Saha A, Sharma A R, Bhattacharya M, Sharma G, Lee S S, Chakraborty C. Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more, *Arch Med Res,* 51(6), 2020, 585-586.
29. Hamming I, Timens W, Bulthuis M L, Lely A T, Navis G, Van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus, A first step in understanding SARS pathogenesis, *J Pathol,* 203(2), 2004, 631-637.
30. Gu J, Han B, Wang J. COVID -19: Gastrointestinal manifestations and potential fecal-oral transmission, *Gastroenterology,* 158(6), 2020, 1518-1519.
31. Chai X Q, Hu L F, Zhang Y, *et al*. Specific ACE2 expression in cholangiocytes may cause liver damage after COVID-19 infection, *Bio Rxiv,* 2020, 1-13.
32. Fan C, Li K, Ding Y, Lu W L, Wang J. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection, *Med Rxiv,* 2020, 1-16.
33. Remdesivir for potential treatment of COVID-19, *Clinical Trials Arena*.
34. Choy K T, Wong A Y, Kaewpreedee P, *et al*. Remdesivir, lopinavir, emetine and homoharringtonine inhibit SARS-CoV-2 replication *in vitro*, *Antiviral Res,* 178, 2020, 104786.
35. Wang M, Cao R, Zhang L, *et al*. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*, *Cell Res,* 30(3), 2020, 269-271.
36. Sheahan T P, Sims A C, Graham R L, *et al*. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, *Sci Transl Med,* 9(396), 2017, eaal3653.
37. Brown A J, Won J J, Graham R L, *et al*. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic delta coronaviruses with a highly divergent RNA dependent RNA polymerase, *Antiviral Res,* 169, 2019, 104541.
38. Pruijssers A J. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice, *Bio Rxiv,* 2020.
39. Wang Y, Zhang D, Du G, *et al*. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial, *Lancet,* 395(10236), 2020, 1569-1578.
40. Grein J, Ohmagari N, Shin D, *et al*. Compassionate use of remdesivir for patients with severe Covid-19, *N Engl J Med,* 382(24), 2020, 2327-2336.
41. Beigel J H, Tomashek K M, Dodd L E, *et al*. Remdesivir for the treatment of COVID-19 - preliminary report, *N Engl J Med,* 2020.
42. Goldman J D, Lye D C B, Hui D S, *et al*. Remdesivir for 5 or 10 days in patients with severe COVID-19, *N Engl J Med,* 383(19), 2020, 1827-1837.
43. Hillaker E, Belfer J J, Bondici A, Murad H, Dumkow L E. Delayed initiation of remdesivir in a COVID-19 positive patient, *Pharmacotherapy,* 40(6), 2020, 592-598.
44. Kujawski S, Wong K K, Collins J P. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States, *Med Rxiv,* 2020, 1-21.
45. https://clinicaltrials.gov/.

**Please cite this article in press as:** Sambhav Pathak *et al*. Remdesivir – Complite pharmacology, *International Journal of Research in Pharmaceutical and Nano Sciences,* 10(5), 2021, 365-371.